Chief Operating Officer Appointed at Aparito
Dr. Elin Haf Davies
Mon Nov 19 2018 10:30:00 GMT+0000 (Coordinated Universal Time)
Aparito is pleased to announce that Cécile Ollivier has been appointed to take on the role of Chief Operating Officer as of 3rd December 2018.
Cécile Ollivier is a senior health engineer with over 10 years of global drug development experience in children and rare disease. Prior to joining Aparito, Cécile was a scientific officer in the Paediatric office and the Science and Innovation office at the European Medicines Agency (EMA). She provided technical and regulatory expert guidance on the design, conduct and interpretation of paediatric developments across multiple therapeutic areas. She has reviewed over 200 paediatric investigation plans (PIPs) and paediatric scientific advice (SA) across all phases of the development. Cécile has been recognised for her work leading the EMA extrapolation strategy and activities including the EMA/FDA harmonisation for Gaucher disease and global harmonisation of criteria for development in paediatric Pulmonary Arterial Hypertension (PAH) with patients, healthcare professionals, FDA and Health Canada. She was also an expert in the E11 R(1) working group and the paediatric standing group for the International Conference of Harmonization (ICH). CEO, Dr Elin Haf Davies said: “I am delighted Cécile has agreed to take on the role of Chief Operating Officer to support me in implementing Aparito’s vision for innovating clinical trials. She is a talented manager and expert with remarkable international track records. This is an important step forward reflecting the company’s growth and development”. Joining Aparito, Cecile’s focus will be on implementing extrapolation strategies across products life cycle based on patient generated data using wearable technology and digital tools. Cécile commented: “I’m delighted to be appointed as Chief Operating Officer for Aparito. This period is a really exciting one for the company as it looks to develop and grow its position as the first-choice patient-generated data (PGD) and Digital Biomarkers company provider for paediatric and rare disease medicines development in Europe, and globally.”